Trial · NCT03810313
Results by group466
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 466
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24 | Brolucizumab 6 mg | 13.2 | Standard Error 0.85 | Letters read | |
| Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 24 | Aflibercept 2 mg | 16.0 | Standard Error 0.85 | Letters read | |
| Change From Baseline in BCVA Averaged Over Week 40 to Week 52 | Brolucizumab 6 mg | 13.4 | Standard Deviation 15.73 | Letters read | |
| Change From Baseline in BCVA Averaged Over Week 40 to Week 52 | Aflibercept 2 mg | 15.4 | Standard Deviation 13.96 | Letters read | |
| Change From Baseline in BCVA Averaged Over Week 64 to Week 76 | Brolucizumab 6 mg | 14.0 | Standard Deviation 16.39 | Letters read | |
| Change From Baseline in BCVA Averaged Over Week 64 to Week 76 | Aflibercept 2 mg | 16.9 | Standard Deviation 13.60 | Letters read | |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 4 | 11.3 | Standard Deviation 12.30 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 4 | 12.8 | Standard Deviation 11.00 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 8 | 13.6 | Standard Deviation 13.77 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 8 | 15.0 | Standard Deviation 11.78 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 12 | 14.1 | Standard Deviation 14.17 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 12 | 16.3 | Standard Deviation 12.78 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 16 | 13.3 | Standard Deviation 15.37 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 16 | 17.4 | Standard Deviation 13.54 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 20 | 13.9 | Standard Deviation 14.17 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 20 | 17.6 | Standard Deviation 14.68 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 24 | 13.6 | Standard Deviation 14.69 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 24 | 18.1 | Standard Deviation 13.83 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Brolucizumab 6 mg | Week 28 | 12.7 | Standard Deviation 15.52 | Letters read |
| Change From Baseline in BCVA by Visit up to Week 76 | Aflibercept 2 mg | Week 28 | 16.2 | Standard Deviation 13.55 | Letters read |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03810313/results